Law360 (April 15, 2011, 10:11 PM EDT) -- Merck & Co. Inc. said Friday it will pay Johnson & Johnson $500 million to end a dispute over rights to two arthritis drugs resulting from Merck's merger with Schering-Plough Corp., and that the two companies plan to share marketing rights.
Merck added it would hand J&J's Janssen unit exclusive marketing rights to the drugs Remicade and Simponi in Canada, Central and South America, the Middle East, Africa, and Asia Pacific on July 1, while retaining marketing rights throughout Europe, Russia and Turkey.
The deal ends an arbitration J&J requested in May 2009 to sever an agreement between subsidiary Centocor Ortho...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!